Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Albin

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cancer Chemotherapy and Pharmacology|July 13, 2023
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumabEmmanuelle Jacquet, Fiona Pham, Billy Taouk, et al.
Frontiers in Pharmacology|May 17, 2021
Collaboration Between Health-Care Professionals, Patients, and National Competent Authorities Is Crucial for Prevention of Health Risks Linked to the Inappropriate Use of Drugs: A Position Paper of the ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)Stéphane Vignot, Pascale Daynes, Trystan Bacon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Individual adaptive dosing of topotecan in ovarian cancerAshraf Montazeri, Stéphane Culine, Brigitte Laguerre, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2021
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 yearsEmmanuelle Jacquet, Ghania Kerouani-Lafaye, Francoise Grude, et al.
Cancer|March 25, 2021
Access to innovation through the national early access program and clinical trials for patients with malignant melanomaClaire Christen, Laetitia Belgodère, Bernard Guillot, et al.
The European Respiratory Journal|February 27, 2016
Idelalisib-related pneumonitisEglantine Haustraete, Julie Obert, Samia Diab, et al.
International Journal of Cancer|May 23, 2022
Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019Fiona Y-V Pham, Emmanuelle Jacquet, Amina Taleb, et al.
Frontiers in Public Health|December 4, 2023
Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experienceLaëtitia Belgodère, Joseph Emmerich, Nicolas Albin, et al.
Therapie|February 27, 2018
Marie-France Mamzer, Sophie Dubois, Christian Saout, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Chemotherapy and Pharmacology|July 13, 2023
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumabEmmanuelle Jacquet, Fiona Pham, Billy Taouk, et al.
Frontiers in Pharmacology|May 17, 2021
Collaboration Between Health-Care Professionals, Patients, and National Competent Authorities Is Crucial for Prevention of Health Risks Linked to the Inappropriate Use of Drugs: A Position Paper of the ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)Stéphane Vignot, Pascale Daynes, Trystan Bacon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Individual adaptive dosing of topotecan in ovarian cancerAshraf Montazeri, Stéphane Culine, Brigitte Laguerre, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2021
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 yearsEmmanuelle Jacquet, Ghania Kerouani-Lafaye, Francoise Grude, et al.
Cancer|March 25, 2021
Access to innovation through the national early access program and clinical trials for patients with malignant melanomaClaire Christen, Laetitia Belgodère, Bernard Guillot, et al.
The European Respiratory Journal|February 27, 2016
Idelalisib-related pneumonitisEglantine Haustraete, Julie Obert, Samia Diab, et al.
International Journal of Cancer|May 23, 2022
Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019Fiona Y-V Pham, Emmanuelle Jacquet, Amina Taleb, et al.
Frontiers in Public Health|December 4, 2023
Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experienceLaëtitia Belgodère, Joseph Emmerich, Nicolas Albin, et al.
Therapie|February 27, 2018
Marie-France Mamzer, Sophie Dubois, Christian Saout, et al.
Pageof 2